Launched in 2022, InAdvance is a Dana-Farber strategic initiative designed to disrupt the historical cancer care model by bringing state-of-the-art early detection and precision intervention to people at higher risk of developing cancer. This integrated research-clinical model will accelerate understanding of precursor conditions that precede cancer and bring earlier interventions for patients more rapidly. This panel discussion will provide an exclusive overview of InAdvance from the initiative’s leaders.